Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Medpace Holdings, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-66.0% vs price
Base Case (Median)
-56.8% vs price
Bull Case (75th pct.)
-28.2% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $258.87 | -56.8% | High (40%) |
| PE Comparable | $382.62 | -36.2% | Medium (25%) |
| Growth Trajectory DCF | $478.64 | -20.2% | Medium (20%) |
| Graham Number | $79.04 | -86.8% | Medium (40%) |
| EV/EBITDA | $215.28 | -64.1% | Medium (20%) |
| EV/FCF | $514.44 | -14.2% | Medium (20%) |
| Earnings Power Value | $192.61 | -67.9% | Medium (50%) |
Based on 7 out of 7 methods, MEDP appears overvalued at the current price of $599.47. The base case fair value of $258.87 implies 56.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.